Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2016-04-04 Board/Management Inform…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Ulf Wiinberg föreslås som ny styrelseordförande och Angelica Loskog som ny styrelseledamot
Board/Management Information Classification · 99% confidence The document is a press release dated April 4, 2016, announcing proposed changes to the Board of Directors of Hansa Medical AB. Specifically, it names Ulf Wiinberg as the proposed new Chairman of the Board and Angelica Loskog as a new board member, while also noting that two current members declined re-election. This content directly relates to changes in senior management and the board structure. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is clearly an announcement of proposed board changes, not a comprehensive annual report (10-K), an audit report (AR), or a general regulatory filing (RNS).
2016-04-04 Swedish
Ulf Wiinberg proposed as new chairman and Angelica Loskog new board member
Board/Management Information Classification · 98% confidence The document is a press release announcing proposed changes to the company's Board of Directors, specifically nominating Ulf Wiinberg as the new chairman and Angelica Loskog as a new board member, while noting others declining re-election. This content directly relates to the composition and changes within the company's governing body. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (3095 chars), but it is the primary announcement itself, not an announcement *about* an attached report, so RPA/RNS is less appropriate than MANG.
2016-04-04 English
Annual Report 2015
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Hansa Medical for the fiscal year 2015. It contains detailed sections including a management review (VD har ordet), financial statements (Räkningar), notes (Noter), auditor's report (Revisionsberättelse), and corporate governance information. It is clearly a full annual report rather than a summary or announcement. FY 2015
2016-03-31 Swedish
Annual Report 2015
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Hansa Medical for the fiscal year 2015. It includes a CEO statement, financial statements, auditor's report, corporate governance report, and detailed business strategy. It is clearly a full annual report rather than an announcement or a summary, as it contains extensive financial data and operational disclosures. FY 2015
2016-03-31 English
Hansa Medical postpones Annual General Meeting
AGM Information Classification · 98% confidence The document is a press release dated March 24, 2016, announcing the postponement of the Annual General Meeting (AGM) from April 27, 2016, to May 11, 2016. This announcement directly relates to the scheduling and logistics of the AGM. While it is not the AGM presentation itself (AGM-R), it is a specific announcement concerning the meeting's date. Given the available codes, AGM-R is the most relevant category as it covers AGM materials, and this is a direct announcement about the meeting's schedule. However, since the document is a short press release announcing a change related to the AGM, and not the AGM materials themselves, it could potentially fall under RNS (Regulatory Filings) if AGM-R is strictly reserved for the presentation/minutes. Given the strong focus on the AGM date change, AGM-R is the best fit among the specific options, as it pertains to the event itself. If a more specific 'AGM Announcement' code existed, it would be preferred. Sticking to the provided definitions, this is an announcement about the AGM event.
2016-03-24 English
Hansa Medical senarelägger årsstämma
Report Publication Announcement Classification · 99% confidence The document is a press release dated March 24, 2016, announcing that Hansa Medical AB is postponing its Annual General Meeting (Årsstämma) from April 27, 2016, to May 11, 2016. The core subject is the scheduling and rescheduling of the AGM. This directly relates to the administrative process surrounding the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R), as it concerns the meeting itself, even though it is an announcement about the date change rather than the meeting materials.
2016-03-24 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.